Mark Yarchoan, M.D., is an Associate Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. His clinical expertise is in the treatment of hepatobiliary cancers, and he leads an NCI-funded laboratory focused on developing innovative immunotherapies, particularly neoantigen-targeted vaccines. Dr. Yarchoan has been at the forefront of advancing therapeutic cancer vaccines for hepatobiliary cancers and has served as Principal Investigator (PI) on several notable clinical trials, including the first clinical trials of a personalized neoantigen vaccine for hepatocellular carcinoma (HCC), neoadjuvant anti-PD1 immunotherapy in HCC, and a neoantigen-specific T-cell vaccine for fibrolamellar hepatocellular carcinoma (FLC). He is also a scientific co-founder of Adventris Therapeutics.

Dr Mark Yarchoan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grant/research support (to Johns Hopkins) from Bristol-Myers Squibb, Exelixis, Incyte, and Genentech;

Honoraria from Exelixis, AstraZeneca, Replimune, Hepion, Lantheus, Genentech, and Incyte

Co-inventor of multiple patents for therapeutic cancer vaccines, and is a cofounder with equity of Adventris Pharmaceuticals, outside of the submitted work.